Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Minority Interest (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Minority Interest for 8 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Minority Interest rose 535.23% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, up 535.23%, and an annual FY2025 reading of $2.2 million, up 535.23% over the prior year.
  • Minority Interest was $2.2 million for Q4 2025 at Abvc Biopharma, down from $2.4 million in the prior quarter.
  • Across five years, Minority Interest topped out at $2.6 million in Q1 2025 and bottomed at -$1.0 million in Q3 2021.
  • Average Minority Interest over 5 years is $251964.0, with a median of -$109654.0 recorded in 2022.
  • The sharpest move saw Minority Interest tumbled 2100.46% in 2024, then skyrocketed 1158.53% in 2025.
  • Year by year, Minority Interest stood at $26689.0 in 2021, then surged by 415.4% to $137554.0 in 2022, then crashed by 318.56% to -$300637.0 in 2023, then tumbled by 67.04% to -$502181.0 in 2024, then surged by 535.23% to $2.2 million in 2025.
  • Business Quant data shows Minority Interest for ABVC at $2.2 million in Q4 2025, $2.4 million in Q3 2025, and $2.5 million in Q2 2025.